RecruitingNot Applicable

Late Onset Alzheimer's Disease

United States10,000 participantsStarted 2016-11-15

Plain-language summary

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

Who can participate

Age range

55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases. * a living sibling with probable or possible AD; * a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older); * participants in the proband's generation with an identified companion serving as an informant; * participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent. Exclusion Criteria: * failure to identify an appropriate informant; * uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder; * discovery of additional diagnosis that could account for the clinical manifestations; * unwillingness to participate; * failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD); * participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Total number of genes identified to be associated with the risk of AD

Timeframe: 5 years

Trial details

NCT IDNCT05010603

SponsorColumbia University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-04-30

Contact for this trial

Dolly Reyes-Dumeyer

212-305-5953 dr2290@cumc.columbia.edu

View on ClinicalTrials.gov More Alzheimer Disease trials